Immunosuppression in Pediatric Kidney Transplantation
Pediatric Kidney Disease, Page: 1849-1886
2023
- 1Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures1
- Readers1
Book Chapter Description
Because it is currently not possible to induce specific tolerance, transplantation requires immunosuppressive therapies. The goal is to use immunosuppressive agents that are potent, selective, and reversible, with reliable delivery and long-term safety. A careful balance is required to find the dose that prevents rejection of the graft, while minimizing the risks of over-immunosuppression leading to infection and cancer. The common immunosuppressive agents used in pediatric renal transplantation include the glucocorticoids, azathioprine, mycophenolate mofetil, the calcineurin inhibitors tacrolimus and ciclosporin, the mammalian target of rapamycin inhibitors sirolimus (SRL) and everolimus, and antibodies to cell surface antigens on lymphocytes (antithymocyte globulin), anti-CD25 antibodies (anti-interleukin-2 receptor antibodies), alemtuzumab (a humanized anti-CD52 pan-lymphocytic monoclonal antibody) and belatacept, a costimulation blocker of T cells. This chapter focuses on these agents and how they inhibit the immune response. Although data from adult renal transplantation trials are used to help guide management decisions in pediatric patients, immunosuppression often must be modified because of the unique clinical effects of some of these agents in children, including their impact on growth and development.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85207160666&origin=inward; http://dx.doi.org/10.1007/978-3-031-11665-0_67; https://link.springer.com/10.1007/978-3-031-11665-0_67; https://dx.doi.org/10.1007/978-3-031-11665-0_67; https://link.springer.com/chapter/10.1007/978-3-031-11665-0_67
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know